CDK4/6 inhibitors in breast cancer: one more step towards reduced mortality

被引：6

作者：

Curigliano, Giuseppe ^{[1
,2
]}

Loibl, Sibylle ^{[3
,4
]}

机构：

[1] IRCCS, Ist Europeo Oncol, I-20141 Milan, Italy

[2] Univ Milan, I-20141 Milan, Italy

[3] GBG Forsch GmbH, Frankfurt, Germany

[4] Bethanien, Ctr Haematol & Oncol, Frankfurt, Germany

来源：

LANCET ONCOLOGY | 2020年 / 21卷 / 02期

关键词：

D O I：

10.1016/S1470-2045(19)30808-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：191 / 192

页数：2

共 10 条

[1] Palbociclib and Letrozole in Advanced Breast Cancer [J].

Finn, Richard S. ;

Martin, Miguel ;

Rugo, Hope S. ;

Jones, Stephen ;

Im, Seock-Ah ;

Gelmon, Karen ;

Harbeck, Nadia ;

Lipatov, Oleg N. ;

Walshe, Janice M. ;

Moulder, Stacy ;

Gauthier, Eric ;

Lu, Dongrui R. ;

Randolph, Sophia ;

Dieras, Veronique ;

Slamon, Dennis J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (20) :1925-1936

[2] CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis [J].

Gao, Jennifer J. ;

Cheng, Joyce ;

Bloomquist, Erik ;

Sanchez, Jacquelyn ;

Wedam, Suparna B. ;

Singh, Harpreet ;

Amiri-Kordestani, Laleh ;

Ibrahim, Amna ;

Sridhara, Rajeshwari ;

Goldberg, Kirsten B. ;

Theoret, Marc R. ;

Kluetz, Paul G. ;

Blumenthal, Gideon M. ;

Pazdur, Richard ;

Beaver, Julia A. ;

Prowell, Tatiana M. .

LANCET ONCOLOGY, 2020, 21 (02) :250-260

[3] Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer [J].

Hortobagyi, G. N. ;

Stemmer, S. M. ;

Burris, H. A. ;

Yap, Y. -S. ;

Sonke, G. S. ;

Paluch-Shimon, S. ;

Campone, M. ;

Blackwell, K. L. ;

Andre, F. ;

Winer, E. P. ;

Janni, W. ;

Verma, S. ;

Conte, P. ;

Arteaga, C. L. ;

Cameron, D. A. ;

Petrakova, K. ;

Hart, L. L. ;

Villanueva, C. ;

Chan, A. ;

Jakobsen, E. ;

Nusch, A. ;

Burdaeva, O. ;

Grischke, E. -M. ;

Alba, E. ;

Wist, E. ;

Marschner, N. ;

Favret, A. M. ;

Yardley, D. ;

Bachelot, T. ;

Tseng, L. -M. ;

Blau, S. ;

Xuan, F. ;

Souami, F. ;

Miller, M. ;

Germa, C. ;

Hirawat, S. ;

O'Shaughnessy, J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (18) :1738-1748

[4] Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3 [J].

Slamon, Dennis J. ;

Neven, Patrick ;

Chia, Stephen ;

Fasching, Peter A. ;

De Laurentiis, Michelino ;

Im, Seock-Ah ;

Petrakova, Katarina ;

Bianchi, Giulia Val ;

Esteva, Francisco J. ;

Martin, Miguel ;

Nusch, Arnd ;

Sonke, Gabe S. ;

De la Cruz-Merino, Luis ;

Beck, J. Thaddeus ;

Pivot, Xavier ;

Vidam, Gena ;

Wang, Yingbo ;

Lorenc, Karen Rodriguez ;

Miller, Michelle ;

Taran, Tetiana ;

Jerusalem, Guy .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (24) :2465-+

[5]

Slamon DJ, 2019, ESMO C 2019 BARC SPA

[6] The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2 A Randomized Clinical Trial [J].

Sledge, George W. ;

Toi, Masakazu ;

Neven, Patrick ;

Sohn, Joohyuk ;

Inoue, Kenichi ;

Pivot, Xavier ;

Burdaeva, Olga ;

Okera, Meena ;

Masuda, Norikazu ;

Kaufman, Peter A. ;

Koh, Han ;

Grischke, Eva-Maria ;

Conte, PierFranco ;

Lu, Yi ;

Barriga, Susana ;

Hurt, Karla ;

Frenzel, Martin ;

Johnston, Stephen ;

Llombart-Cussac, Antonio .

JAMA ONCOLOGY, 2020, 6 (01) :116-124

[7] MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy [J].

Sledge, George W., Jr. ;

Toi, Masakazu ;

Neven, Patrick ;

Sohn, Joohyuk ;

Inoue, Kenichi ;

Pivot, Xavier ;

Burdaeva, Olga ;

Okera, Meena ;

Masuda, Norikazu ;

Kaufman, Peter A. ;

Koh, Han ;

Grischke, Eva-Maria ;

Frenzel, Martin ;

Lin, Yong ;

Barriga, Susana ;

Smith, Ian C. ;

Bourayou, Nawel ;

Llombart-Cussac, Antonio .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (25) :2875-+

[8] Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial [J].

Tripathy, Debu ;

Im, Seock-Ah ;

Colleoni, Marco ;

Franke, Fabio ;

Bardia, Aditya ;

Harbeck, Nadia ;

Hurvitz, Sara A. ;

Chow, Louis ;

Sohn, Joohyuk ;

Lee, Keun Seok ;

Campos-Gomez, Saul ;

Vazquez, Rafael Villanueva ;

Jung, Kyung Hae ;

Babu, K. Govind ;

Wheatley-Price, Paul ;

De laurentiis, Michelino ;

Im, Young-Hyuck ;

Kuemmel, Sherko ;

El-Saghir, Nagi ;

Liu, Mei-Ching ;

Carlson, Gary ;

Hughes, Gareth ;

Diaz-Padilla, Ivan ;

Germa, Caroline ;

Hirawat, Samit ;

Lu, Yen-Shen .

LANCET ONCOLOGY, 2018, 19 (07) :904-915

[9] Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer [J].

Turner, N. C. ;

Slamon, D. J. ;

Ro, J. ;

Bondarenko, I ;

Im, S-A ;

Masuda, N. ;

Colleoni, M. ;

DeMichele, A. ;

Loi, S. ;

Verma, S. ;

Iwata, H. ;

Harbeck, N. ;

Loibl, S. ;

Andre, F. ;

Puyana Theall, K. ;

Huang, X. ;

Giorgetti, C. ;

Huang Bartlett, C. ;

Cristofanilli, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (20) :1926-1936

[10] Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial [J].

van Ommen-Nijhof, A. ;

Konings, I. R. ;

van Zeijl, C. J. J. ;

Uyl-de Groot, C. A. ;

van der Noort, V. ;

Jager, A. ;

Sonke, G. S. .

BMC CANCER, 2018, 18

← 1 →